Spots Global Cancer Trial Database for MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Official Title: Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Study ID: NCT00207103
Study Description
Brief Summary: This is a Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in patients with advanced or metastatic solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Premiere Oncology, Santa Monica, California, United States
Indiana University Med Center, Indianapolis, Indiana, United States
University Of Wisconsin Comprehensive Center, Madison, Wisconsin, United States
Local Institution, Edmonton, Alberta, Canada
Local Institution, Ottawa, Ontario, Canada
Local Institution, Milano, , Italy
Local Institution, Middlesex, Greater London, United Kingdom
Local Institution, Manchester, Greater Manchester, United Kingdom
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
